{"product_id":"the-ada-practical-guide-to-substance-use-disorders-and-safe-prescribing-isbn-9781118886014","title":"The ADA Practical Guide to Substance Use Disorders and Safe Prescribing","description":"\u003cp\u003eDentists have been inundated by patients with an array of complicated medical conditions and pain\/sedation management issues. This is in addition to a variety of legal regulations dentists must follow regarding the storage and recordkeeping of controlled substances. Avoid unknowingly putting your practice at risk by becoming victim to a scam or violating a recordkeeping requirement with The \u003ci\u003eADA Practical Guide to Substance Use Disorders and Safe Prescribing\u003c\/i\u003e.\u003c\/p\u003e \u003cp\u003eThis \u003ci\u003ePractical Guide\u003c\/i\u003e is ideal for dentists and staff as they navigate:\u003c\/p\u003e \u003cp\u003e• Detecting and deterring substance use disorders (SUD) and drug diversion in the dental office (drug-seeking patients)\u003cbr\u003e • Prescribing complexities\u003cbr\u003e • Treating patients with SUD and complex analgesic and sedation (pain\/sedation management) needs and the best use of sedation anxiety medication\u003cbr\u003e • Interviewing and counselling options for SUD\u003cbr\u003e • Federal drug regulations\u003cbr\u003e Commonly used illicit, prescription, and over-the-counter drugs, as well as alcohol and tobacco, are also covered.\u003c\/p\u003e \u003cp\u003eSpecial features include:\u003c\/p\u003e \u003cp\u003e• Clinical tools proven to aid in the identification, interviewing, intervention, referral and treatment of SUD\u003cbr\u003e • Basic elements of SUD, acute pain\/sedation management, and drug diversion\u003cbr\u003e • Summary of evidence-based literature that supports what, when and how to prescribe controlled substances to patients with SUD\u003cbr\u003e • Discussion of key federal controlled substance regulations that frequently impact dental practitioners\u003cbr\u003e • Checklists to help prevent drug diversion in dental practices\u003cbr\u003e • Chapter on impaired dental professionals\u003cbr\u003e • Case studies that examine safe prescribing and due diligence\u003c\/p\u003e \u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003eAcknowledgments xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Substance Use Disorders, Drug Diversion, and Pain Management: The Scope of the Problem 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichael O’Neil, PharmD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 1\u003c\/p\u003e \u003cp\u003eDefinitions 2\u003c\/p\u003e \u003cp\u003eSubstance Use Disorder, Drug Misuse, Drug Diversion, and Pain Management in the Dental Community 4\u003c\/p\u003e \u003cp\u003eUnderstanding the Cultures of Substance Use Disorder, Drug Misuse, and Drug Diversion 8\u003c\/p\u003e \u003cp\u003eSummary 9\u003c\/p\u003e \u003cp\u003eReferences 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Understanding the Disease of Substance Use Disorders 11\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJames H. Berry, DO and Carl Rollynn Sullivan, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 11\u003c\/p\u003e \u003cp\u003eDefinitions 11\u003c\/p\u003e \u003cp\u003eEpidemiology: Drug\/Alcohol 13\u003c\/p\u003e \u003cp\u003ePathophysiology\/Brain Pathways 14\u003c\/p\u003e \u003cp\u003eSigns, Symptoms, Behavior 15\u003c\/p\u003e \u003cp\u003eTreatment Methods 20\u003c\/p\u003e \u003cp\u003eSummary 26\u003c\/p\u003e \u003cp\u003eAppendix 2.A: Common Opioid Analgesics and their Brand Names 27\u003c\/p\u003e \u003cp\u003eReferences 29\u003c\/p\u003e \u003cp\u003eResources and Further Readings 30\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Principles of Pain Management in Dentistry 31\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePaul A. Moore, DMD, PhD, MPH and Elliot V. Hersh, DMD, MS, PhD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 31\u003c\/p\u003e \u003cp\u003eDefinitions 32\u003c\/p\u003e \u003cp\u003eNeurophysiology and Neuroanatomy of Acute Inflammatory Pain 32\u003c\/p\u003e \u003cp\u003eOrally Administered Analgesic Agents 33\u003c\/p\u003e \u003cp\u003eMedication-Assisted Therapies for Treating Drug-Dependent Patients 41\u003c\/p\u003e \u003cp\u003eAdjunctive Drugs Used to Limit Pain in Dentistry 41\u003c\/p\u003e \u003cp\u003eGuidelines for Analgesic Therapy 43\u003c\/p\u003e \u003cp\u003eSummary 45\u003c\/p\u003e \u003cp\u003eReferences 45\u003c\/p\u003e \u003cp\u003eResources and Further Readings 46\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Special Pain Management Considerations: (1) Chronic Methadone, Buprenorphine, and Naltrexone Therapy; (2) Chronic Opioids for Nonmalignant Pain 47\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichael O’Neil, PharmD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 47\u003c\/p\u003e \u003cp\u003eDefinitions 48\u003c\/p\u003e \u003cp\u003eInterviewing the Patient: Establishing Goals of Treatment 49\u003c\/p\u003e \u003cp\u003ePharmacological Treatment of Opioid Addiction 49\u003c\/p\u003e \u003cp\u003eTreating Acute Dental Pain 51\u003c\/p\u003e \u003cp\u003eAcute Pain in Patients Receiving Opioid Maintenance Therapy 51\u003c\/p\u003e \u003cp\u003eThe Active Opioid Addict 55\u003c\/p\u003e \u003cp\u003eAcute Pain Management in Patients Receiving Naltrexone Therapy 56\u003c\/p\u003e \u003cp\u003eAcute Pain Management in Patients Receiving Opioids for Chronic Pain 57\u003c\/p\u003e \u003cp\u003eSummary 57\u003c\/p\u003e \u003cp\u003eReferences 58\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Sedation and Anxiolysis 61\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMatthew Cooke, DDS, MD, MPH\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 61\u003c\/p\u003e \u003cp\u003eDefinitions 61\u003c\/p\u003e \u003cp\u003eSpectrum of Anesthesia and Sedation 62\u003c\/p\u003e \u003cp\u003ePreoperative Evaluation 64\u003c\/p\u003e \u003cp\u003ePhysical Status Classification 65\u003c\/p\u003e \u003cp\u003eSedation 65\u003c\/p\u003e \u003cp\u003eMedications Available for Sedation of Patients with Substance Use Disorder 68\u003c\/p\u003e \u003cp\u003eThe Concept of Balanced Anesthesia 76\u003c\/p\u003e \u003cp\u003eMonitoring and Documentation 76\u003c\/p\u003e \u003cp\u003eSummary 78\u003c\/p\u003e \u003cp\u003eDisclaimer 78\u003c\/p\u003e \u003cp\u003eReferences 79\u003c\/p\u003e \u003cp\u003eResources and Further Readings 82\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Common Substances and Medications of Abuse 83\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eWilliam J. Maloney, DDS and George F. Raymond, DDS\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 83\u003c\/p\u003e \u003cp\u003eDefinitions 83\u003c\/p\u003e \u003cp\u003eSigns and Symptoms of Substance Use Disorder 85\u003c\/p\u003e \u003cp\u003eCommon Substances of Abuse 86\u003c\/p\u003e \u003cp\u003ePrescription Medications 100\u003c\/p\u003e \u003cp\u003eOver-the-Counter Medications 111\u003c\/p\u003e \u003cp\u003eSummary 112\u003c\/p\u003e \u003cp\u003eReferences 112\u003c\/p\u003e \u003cp\u003eResources and Further Readings 118\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Tobacco Cessation: Behavioral and Pharmacological Considerations 119\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eFrank Vitale, MA and Amanda Eades, PharmD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 119\u003c\/p\u003e \u003cp\u003eDefinitions 119\u003c\/p\u003e \u003cp\u003eForms of Tobacco 121\u003c\/p\u003e \u003cp\u003eOral Effects of Tobacco Use 121\u003c\/p\u003e \u003cp\u003eDental Practitioner Management of Tobacco Use 122\u003c\/p\u003e \u003cp\u003eSpit Tobacco Interventions 124\u003c\/p\u003e \u003cp\u003eOral Substitutes 125\u003c\/p\u003e \u003cp\u003eSocial Support\/Disapproval 125\u003c\/p\u003e \u003cp\u003eMedication Management for Smoking Cessation 126\u003c\/p\u003e \u003cp\u003eThe Role of Nicotine 126\u003c\/p\u003e \u003cp\u003ePharmacotherapy Options 127\u003c\/p\u003e \u003cp\u003eSummary 138\u003c\/p\u003e \u003cp\u003eReferences 138\u003c\/p\u003e \u003cp\u003eResources and Further Readings 140\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Detection and Deterrence of Substance Use Disorders and Drug Diversion in Dental Practice 141\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSarah T. Melton, PharmD, BCPP, BCACP, CGP, FASCP and Ralph A. Orr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 141\u003c\/p\u003e \u003cp\u003eDefinitions 141\u003c\/p\u003e \u003cp\u003eScreening Patients for Substance Use Disorder 142\u003c\/p\u003e \u003cp\u003eSchemes and Scams to Obtain Prescription Drugs 144\u003c\/p\u003e \u003cp\u003eDental Practitioner- and Office Personnel-Related Prescription Drug Diversion 147\u003c\/p\u003e \u003cp\u003ePrescription Drug Monitoring Programs 148\u003c\/p\u003e \u003cp\u003eDisposal of Controlled Substances 153\u003c\/p\u003e \u003cp\u003eUniversal Precautions in Prescribing Controlled Substances 154\u003c\/p\u003e \u003cp\u003eSummary 157\u003c\/p\u003e \u003cp\u003eReferences 157\u003c\/p\u003e \u003cp\u003eResources and Further Readings 158\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Interviewing and Counseling Patients with Known or Suspected Substance Use Disorders: Dealing with Drug-seeking Patients 159\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGeorge F. Raymond, DDS and William J. Maloney, DDS\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 159\u003c\/p\u003e \u003cp\u003eDefinitions 160\u003c\/p\u003e \u003cp\u003ePreinterview Considerations 160\u003c\/p\u003e \u003cp\u003ePatient Interview Considerations 161\u003c\/p\u003e \u003cp\u003eInterviewing and Counseling Techniques 162\u003c\/p\u003e \u003cp\u003eWhat Questions Should Be Asked? 163\u003c\/p\u003e \u003cp\u003eScreening Tools 164\u003c\/p\u003e \u003cp\u003eDocumentation 165\u003c\/p\u003e \u003cp\u003eSummary 166\u003c\/p\u003e \u003cp\u003eReferences 166\u003c\/p\u003e \u003cp\u003eResources and Further Readings 167\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Office Management of Controlled Substances 169\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCarlos M. Aquino\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 169\u003c\/p\u003e \u003cp\u003eFederal Statutes and Regulations 169\u003c\/p\u003e \u003cp\u003eDefinitions 169\u003c\/p\u003e \u003cp\u003eCommon Violations by Dental Practitioners 170\u003c\/p\u003e \u003cp\u003eSurviving a Drug Enforcement Administration Inspection 173\u003c\/p\u003e \u003cp\u003ePractice Due Diligence Program 175\u003c\/p\u003e \u003cp\u003eManagement of Noncontrolled Substances in the Office 176\u003c\/p\u003e \u003cp\u003eSummary 176\u003c\/p\u003e \u003cp\u003eResources and Further Readings 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Addiction and Impairment in the Dental Professional 177\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eWilliam T. Kane, DDS, MBA, FAGD, FACD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 177\u003c\/p\u003e \u003cp\u003eDefinitions 178\u003c\/p\u003e \u003cp\u003eThe Complexity of Addiction 178\u003c\/p\u003e \u003cp\u003eThe Neurobiology of Addiction 179\u003c\/p\u003e \u003cp\u003eThe Stigma of Addiction 180\u003c\/p\u003e \u003cp\u003eEpidemiology of Addiction in Dentistry 180\u003c\/p\u003e \u003cp\u003eRisk Factors for Substance Use Disorder 180\u003c\/p\u003e \u003cp\u003eSubstances of Choice 182\u003c\/p\u003e \u003cp\u003eIdentifying Addiction 183\u003c\/p\u003e \u003cp\u003e“The Conspiracy of Silence” 183\u003c\/p\u003e \u003cp\u003eIntervention 184\u003c\/p\u003e \u003cp\u003eEvaluation\/Assessment 185\u003c\/p\u003e \u003cp\u003eTreatment 186\u003c\/p\u003e \u003cp\u003eFamily and Staff 186\u003c\/p\u003e \u003cp\u003eRelapse 187\u003c\/p\u003e \u003cp\u003eMonitoring 187\u003c\/p\u003e \u003cp\u003ePeer Assistance or Dental Well-being Committee Programs 187\u003c\/p\u003e \u003cp\u003eSummary 189\u003c\/p\u003e \u003cp\u003eReferences 189\u003c\/p\u003e \u003cp\u003eResources and Further Readings 190\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Due Diligence and Safe Prescribing 191\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichael O’Neil, PharmD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 191\u003c\/p\u003e \u003cp\u003eDefinitions 191\u003c\/p\u003e \u003cp\u003eCase Scenarios 192\u003c\/p\u003e \u003cp\u003eSummary 205\u003c\/p\u003e \u003cp\u003eReferences 206\u003c\/p\u003e \u003cp\u003eContinuing Education Examination 207\u003c\/p\u003e \u003cp\u003eIndex 213\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eMichael O’Neil\u003c\/b\u003e, Pharm.D., is Professor and Vice Chair of the Department of Pharmacy Practice at South College School of Pharmacy in Knoxville, Tennessee. Dr. O’Neil has more than 25 years’ experience as a critical care and pain specialist and has taught pharmacy students, pharmacy residents, nursing students, surgery\/medical students, and medical residents in the classroom and at the bedside. He has completed research and published in several leading health professional journals including pharmacy, dentistry, and nursing. Dr. O’Neil has also served as a consultant and expert on prescription drug abuse, substance abuse, and drug diversion for the U.S. Drug Enforcement Agency, the Bureau of Criminal Investigation, the U.S. Attorney’s Office, the West Virginia Board of Dental Examiners, the American Association of Dental Boards, and several law enforcement agencies. Dr. O’Neil developed the West Virginia Pharmacists Recovery Network where he served as Executive Director and head investigator. Dr. O’Neil helped initiate other professional recovery networks in medicine, dentistry and nursing.\u003c\/p\u003e  \u003cp\u003eDentists have been inundated by patients with an array of complicated medical conditions and pain\/sedation management issues. This is in addition to a variety of legal regulations dentists must follow regarding the storage and recordkeeping of controlled substances. Avoid unknowingly putting your practice at risk by becoming victim to a scam or violating a recordkeeping requirement with \u003ci\u003eThe ADA Practical Guide to Substance Use Disorders and Safe Prescribing.\u003cbr\u003e \u003c\/i\u003e\u003cbr\u003e This \u003ci\u003ePractical Guide\u003c\/i\u003e is ideal for dentists and staff as they navigate: \u003c\/p\u003e \u003cul\u003e \u003cli\u003eDetecting and deterring substance use disorders (SUD) and drug diversion in the dental office (drug-seeking patients)\u003c\/li\u003e \u003cli\u003ePrescribing complexities\u003c\/li\u003e \u003cli\u003eTreating patients with SUD and complex analgesic and sedation (pain\/sedation management) needs and the best use of sedation anxiety medication\u003c\/li\u003e \u003cli\u003eInterviewing and counselling options for SUD\u003c\/li\u003e \u003cli\u003eFederal drug regulations\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eCommonly used illicit, prescription, and over-the-counter drugs, as well as alcohol and tobacco, are also covered. \u003c\/p\u003e \u003cp\u003eSpecial features include: \u003c\/p\u003e \u003cul\u003e \u003cli\u003eClinical tools proven to aid in the identification, interviewing, intervention, referral and treatment of SUD\u003c\/li\u003e \u003cli\u003eBasic elements of SUD, acute pain\/sedation management, and drug diversion\u003c\/li\u003e \u003cli\u003eSummary of evidence-based literature that supports what, when and how to prescribe controlled substances to patients with SUD\u003c\/li\u003e \u003cli\u003eDiscussion of key federal controlled substance regulations that frequently impact dental practitioners\u003c\/li\u003e \u003cli\u003eChecklists to help prevent drug diversion in dental practices\u003c\/li\u003e \u003cli\u003eChapter on impaired dental professionals\u003c\/li\u003e \u003cli\u003eCase studies that examine safe prescribing and due diligence\u003c\/li\u003e \u003c\/ul\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990152331493,"sku":"NP9781118886014","price":78.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118886014.jpg?v=1761786703","url":"https:\/\/k12savings.com\/es\/products\/the-ada-practical-guide-to-substance-use-disorders-and-safe-prescribing-isbn-9781118886014","provider":"K12savings","version":"1.0","type":"link"}